Shell PLC (LSE:SHEL, NYSE:SHEL) management and strategy changes last year are now bearing fruit, that’s according to analysts at Berenberg – which today repeated a ‘buy’ recommendation.
The European investment bank highlighted Shell’s strong cash flow growth, helped by cost discipline.
Inditex’s impressive results yesterday have prompted Canadian bank RBC to up its forecasts but it still prefers JD Sports Fashion PLC (LSE:JD.) and Zalando.
The Zara owner’s price target is now €50 from €48, with the growth of 11% in revenues in the third quarter so far seen as 'very reassuring' by the bank.
Changes to capital gains tax rumoured to be one of the key planks of the Budget on 30 October are likely to have major implications for investors and potentially even send them towards capital lossmakers, says Stifel.
“Any increase in CGT rates and reduction in ISA allowances would be unhelpful both for the investment companies sector and are likely to discourage savings and investments more generally,” says the US broker.
Rentokil Initial PLC (LSE:RTO) has had its targets cut by Deutsche Bank analysts after warning over sluggish sales in North America.
Deutsche analysts said the pest controller’s pre-tax profit was now expected to sit at £691 million for the year, 11% lower than previously thought.
The Bank of England's regulatory arm has published new capital rules for the UK's major banks, which analysts said "looks like positive news" for the sector.
The Prudential Regulation Authority published a 245-page report today revealing its 'near-final' implementation of the Basel III standards, which led to gains for larger lenders such as Lloyds and Barclays.
Ecora Resources PLC (LSE:ECOR, TSX:ECOR, OTCQX:ECRAF) is undervalued by the market and currently stands at a discount to even the worst-case prognosis, says broker Berenberg.
A mining royalty stream specialist, Berenberg notes Ecora's key commodities such as cobalt and metallurgical coal have come under pressure this year.
Analysts following Futura Medical PLC (AIM:FUM, OTC:FAMDF) have updated and significantly upgraded revenue forecasts in the wake of its better-than-expected interims - results that saw the sexual healthcare group post a maiden profit ahead of schedule.
It told investors that the City's abacus rattlers now see turnover for this year in the region of £13.4 million, rising to £18.6 million for 2025.